Scientists Engineer Plant to Produce Multiple Psychedelic Compounds Simultaneously

In a groundbreaking scientific endeavor, researchers at the Weizmann Institute of Science have successfully engineered a single plant to produce five different well-known psychedelic substances simultaneously. These compounds, naturally scattered across the plant, animal, and fungi kingdoms, have historically been used in rituals, healing practices, and mental health treatments. This pioneering work involved deciphering the natural biosynthetic pathway of one of the most prominent psychedelics, DMT, and then meticulously re-engineering this process, along with pathways for four other compounds, into a model plant. The study, led by Dr. Paula (Shirley) Berman and conducted in Prof. Asaph Aharoni's lab, focused on five distinct psychedelic compounds: DMT (from plants), psilocybin and psilocin (from fungi, known as 'magic mushrooms'), and bufotenin and 5-MeO-DMT (from the Sonoran Desert toad). Despite their diverse origins, all five compounds belong to the same chemical family and share a common biological precursor, tryptophan—a common amino acid also used by the human body to produce serotonin. This shared origin helps explain their similar interactions with brain receptors. A significant challenge involved mapping the precise genes and enzymes responsible for DMT production, a pathway previously understood only in general terms. The team successfully identified these key genetic components and inserted them into *Nicotiana benthamiana*, a tobacco relative commonly used in research. This 'taught' the plant to produce DMT. Further challenges arose when attempting to produce 5-MeO-DMT, which initially yielded surprisingly low amounts. Through collaboration with protein design experts, a single amino acid mutation in an enzyme's structure dramatically improved production by 40-fold, demonstrating the power of targeted metabolic engineering. Following these successes, the scientists introduced the genes for all five compounds into the same plant. The system proved effective, creating a 'biological cocktail' where a single organism produced all five psychedelics. However, this simultaneous activation revealed an important limitation: the pathways began to compete for the same starting material, leading to a bottleneck and a drop in production efficiency. This highlights a critical area for future optimization in metabolic engineering. Pushing the boundaries beyond natural evolution, the team also incorporated bacterial enzymes to create modified psychedelic molecules. These novel compounds, carrying chlorine or bromine atoms in specific positions, do not occur naturally but have already shown intriguing biological activity, including antidepressant effects. This innovative approach not only demonstrates the potential for sustainable and controlled production of existing psychedelics but also opens doors for the discovery and synthesis of entirely new molecules with potentially valuable therapeutic applications, marking a significant step forward in biotechnology and medicine.